PDS Biotechnology Corporation (PDSB) financial statements (2021 and earlier)

Company profile

Business Address 25B VREELAND ROAD
FLORHAM PARK, NJ 07932
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments29123588106130
Cash and cash equivalents29123588106130
Other undisclosed current assets121111
Total current assets:30143689107131
Noncurrent Assets
Operating lease, right-of-use asset1 
Property, plant and equipment000333
Intangible assets, net (including goodwill) 3    
Intangible assets, net (excluding goodwill) 3    
Other noncurrent assets  0000
Other undisclosed noncurrent assets (3)    
Total noncurrent assets:101443
TOTAL ASSETS:31143693111134
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3211076
Accounts payable110433
Accrued liabilities210534
Debt   3 2
Restructuring reserve 06   
Other undisclosed current liabilities0     
Total current liabilities:3361379
Noncurrent Liabilities
Long-term debt and lease obligation0  17153
Long-term debt, excluding current maturities   17153
Operating lease, liability0 
Other undisclosed noncurrent liabilities(0)     
Total noncurrent liabilities:0  17153
Total liabilities:436302212
Stockholders' equity
Stockholders' equity attributable to parent2712306289122
Common stock000000
Additional paid in capital7141223214190185
Accumulated deficit(44)(29)(193)(152)(101)(62)
Total stockholders' equity:2712306289122
TOTAL LIABILITIES AND EQUITY:31143693111134

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Operating expenses(15)(21)(43)(52)(40)(26)
Operating loss:(15)(21)(43)(52)(40)(26)
Nonoperating income0141100
Investment income, nonoperating0141100
Other nonoperating expense    (0) 
Interest and debt expense (0)(1)(2)(1)(1)
Other undisclosed loss from continuing operations before equity method investments, income taxes     (2)
Loss from continuing operations before income taxes:(15)(7)(44)(53)(41)(29)
Income tax expense (benefit) (0)3321
Net loss:(15)(8)(41)(51)(39)(28)
Other undisclosed net income attributable to parent 1    
Net loss attributable to parent:(15)(7)(41)(51)(39)(28)
Preferred stock dividends and other adjustments     (4)
Net loss available to common stockholders, diluted:(15)(7)(41)(51)(39)(32)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(15)(8)(41)(51)(39)(28)
Comprehensive loss:(15)(8)(41)(51)(39)(28)
Other undisclosed comprehensive income, net of tax, attributable to parent 1    
Comprehensive loss, net of tax, attributable to parent:(15)(7)(41)(51)(39)(28)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: